Valuation : Onconic Therapeutics Inc.

Market Cap 671B 487M 419M 393M 359M 676M 46.51B 678M 4.66B 1.82B 23.48B 1.83B 1.79B 77.85B P/E 2024
-16.5x
P/E 2025 56.2x
Enterprise Value 618B 448M 386M 362M 331M 623M 42.86B 625M 4.3B 1.68B 21.64B 1.68B 1.65B 71.74B EV / Sales 2024
9.02x
EV / Sales 2025 15.3x
Free-Float
50.62%
Yield 2024 *
-
Yield 2025 -
1 day+2.78%
1 week+0.27%
Current month+36.51%
1 month+33.18%
3 months-25.40%
6 months-37.15%
Current year-24.45%
1 week 13,820
Extreme 13820
14,900
1 month 8,790
Extreme 8790
16,920
Current year 8,790
Extreme 8790
28,900
1 year 6,450
Extreme 6449.999999
28,900
3 years 3,137.5
Extreme 3137.5
28,900
5 years 3,137.5
Extreme 3137.5
28,900
10 years 3,137.5
Extreme 3137.5
28,900
Manager TitleAgeSince
Chief Executive Officer 59 31/12/2019
Director of Finance/CFO 50 31/12/2019
Chief Tech/Sci/R&D Officer 59 -
Director TitleAgeSince
Director/Board Member 50 31/12/2019
Director/Board Member 59 31/12/2019
Director/Board Member 44 25/03/2024
Date Insider Type Main position Quantity % Market Cap.
22/04/25 Fiscal year 50,000 0.4595%
18/04/25 Fiscal year

Chief Technology Officer

12,500 0.1149%
17/04/25 Fiscal year

Chief Financial Officer

18,100 0.1663%
Change 5-day change 1-year change 3-year change Capi.($)
+2.78%+0.27%+124.64% - 472M
-1.59%-6.25%+64.99%+99.09% 70.64B
-1.34%+1.13%+47.33%+90.79% 66.11B
-8.37%-7.95%-0.91%-13.21% 27.98B
-2.35%-5.23%-11.89%+442.77% 26.51B
+0.30%+2.03%+59.48%+14.21% 26.44B
-0.96%+12.36%+280.38%+439.54% 20.4B
-0.51%+0.70%+35.85%-16.21% 20.17B
-1.91%-3.47%+11.03%+508.52% 15.99B
-1.47%+1.42%+41.39%+147.61% 13.69B
Average -1.54%+1.18%+65.23%+190.35% 28.84B
Weighted average by Cap. -1.97%+1.23%+56.16%+151.22%

Financials

2024 2025
Net sales 14.84B 10.77M 9.28M 8.7M 7.94M 14.96M 1.03B 15.01M 103M 40.26M 519M 40.42M 39.54M 1.72B 53.39B 38.74M 33.38M 31.3M 28.57M 53.82M 3.7B 54M 371M 145M 1.87B 145M 142M 6.2B
Net income -8.09B -5.87M -5.06M -4.74M -4.33M -8.16M -561M -8.18M -56.28M -21.96M -283M -22.05M -21.57M -939M 15.78B 11.45M 9.87M 9.25M 8.45M 15.91M 1.09B 15.96M 110M 42.83M 553M 43M 42.06M 1.83B
Net Debt -42.69B -30.98M -26.69M -25.03M -22.84M -43.04M -2.96B -43.17M -297M -116M -1.49B -116M -114M -4.96B -52.61B -38.17M -32.89M -30.84M -28.15M -53.03M -3.65B -53.2M -366M -143M -1.84B -143M -140M -6.11B
Logo Onconic Therapeutics Inc.
Onconic Therapeutics Inc is a Korea-based company principally engaged in the new drugs research and development business. The Company mainly develops new drugs and treatments in the acid-related diseases, digestive diseases and anticancer fields based on small molecules. The Company’s products include acid-related disease treatment drug Zastaprazan and synthetic lethal deoxyribonucleic acid (DNA) damage repair inhibitor anticancer drug Nesuparib.
Employees
-
Date Price Change Volume
27/08/26 14,770.00 +2.78% 262,751
27/08/26 ₩14,370.00 -0.62% 123,532
26/08/26 ₩14,460.00 +0.63% 188,581
25/08/26 ₩14,370.00 -1.03% 176,015
24/08/26 ₩14,520.00 0.00% 228,054
  1. Stock Market
  2. Stocks
  3. A476060 Stock